Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

Also called NCT05735197

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05735197
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05735197. Randomized; single masking; primary purpose prevention. Start 2022-09-01 (actual); primary completion 2023-08-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients
Condition
Chronic Kidney Diseases
Condition
Bone Diseases, Metabolic
Intervention (Drug)
Dapagliflozin 10mg Tab
Intervention (Drug)
Placebo
Lead sponsor
Mansoura University (class: other)

Record details

Record id
cardio:ct-nct05735197
Content hash
dd2ee625cce7580fe97eba092e5eee024d656b86e70127c475fa9588545f0877